Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 86 of 110 Updated Nov 17, 2026

Nonapeptide-1

Melanostatine-5

COSMETIC CLINICAL STUDIES · COSMETIC PEPTIDE; MC1R ANTAGONIST

▓ 6 indexed citations across PubMed (3), EuropePMC (3).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

6 citations across 2 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Blocks α-MSH binding at MC1R; reduces melanogenesis

Researched effects

Skin brightening; pigment control

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

Topical 0.01-0.05%

Known concerns

Minimal

Top-ranked picks

6 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. A randomized controlled pilot study of a proprietary combination versus sunscreen in melasma maintenance.

    Indian journal of dermatology, venereology and leprology · 2021 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.1

  2. Discovery of a Novel Cyclopeptide as Tyrosinase Inhibitor for Skin Lightening.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  3. Stellarin I: A Bioactive Cyclic Nonapeptide with Potent Anti-renal Fibrosis Activity from the Root of Stellaria yunnanensis Franch.

    2025 — RESEARCH ARTICLES · AUTHORITY 34.5

  4. Enhanced skin benefits of EGCG loaded in nonapeptide-1-conjugated mesoporous silica nanoparticles to reverse skin photoaging.

    International journal of pharmaceutics · 2024 — RESEARCH ARTICLES · AUTHORITY 34.4

  5. Effects of tea polyphenols on UVA-induced melanogenesis via inhibition of α-MSH-MC1R signalling pathway.

    Postepy dermatologii i alergologii · 2022 — RESEARCH ARTICLES · AUTHORITY 34.2

  6. Efficacy, Safety and Targets in Topical and Transdermal Active and Excipient Delivery

    2017 — RESEARCH ARTICLES · AUTHORITY 33.7

Full citation library

Year distribution

Randomised Controlled Trials

1
  1. 1.

    Chatterjee M, Neema S, Rajput GR · Indian journal of dermatology, venereology and leprology · 2021 · PMID 34379946

    Melasma is the commonest cause of facial hypermelanosis in skin type IV-VI. First-line treatment includes a triple combination containing topical corticosteroid and hydroquinone which have side effects on prolonged use. Chemical peels are a second-line management option with the laser being used in refractory cases, but the worsening of hyperpigmentation in darker skin types can occur following laser therapy. Sunscreen is a must to prevent relapses. (i) To compare the effects of treatment with a…

Research Articles

5
  1. 2.

    Huang ZJ, Zhou XH, Wen WQ, Huang ZT, et al. · International journal of pharmaceutics · 2024 · PMID 39260749

    Epigallocatechin-3-gallate (EGCG), a catechin present in green tea, has been studied extensively for its potential as a cosmetic ingredient due to its various biological properties. However, the low stability and bioavailability of EGCG have hindered its effective utilization in cosmetic applications. This study, to improve the stability and bioavailability of EGCG for reversing skin photo-aging, nonapeptide-1-conjugated mesoporous silica nanoparticles (EGCG@NP-MSN) were fabricated to load EGCG.…

  2. 3.

    Chen J, Li H, Liang B, Zhu H · Postepy dermatologii i alergologii · 2022 · PMID 35645678

    Ultraviolet (UV) irradiation is a major environmental factor affecting photoaging, which is characterized by skin wrinkle formation and hyperpigmentation. Although many factors are involved in the melanogenesis progress, UV is thought to play a major role in tanning. The pathway of α-melanocyte-stimulating hormone (α-MSH)-melanocortin receptor 1 (MC1R) is associated with UV-induced melanogenesis. Thus, α-MSH antagonists may have applications in the prevention of melanogenesis. To investigate the…

  3. 4.

    Chang H, Tao K, Huang H, Jia J, Khan SN, Cui J. · 2025 · PMID 40939092

    <h4>Background</h4>Melanin synthesis plays a crucial role in skin pigmentation, and inhibiting tyrosinase, the key enzyme in melanin production, is a primary strategy for developing skin-lightening agents. This study investigates the tyrosinase inhibitory potential of CHP-9, a novel cyclopeptide, and evaluates its cytotoxicity and efficacy as a cosmetic depigmenting agent.<h4>Methods</h4>CHP-9 was synthesized via a solid-phase peptide synthesis strategy. The tyrosinase inhibitory activity was as…

  4. 5.

    Deng R, Gu C, Wang J, Li X, Xin X, Yang Y, Li J, Xia C, An F. · 2025 · PMID 40789062

    An undescribed cyclic nonapeptide (1) was isolated from the crude root extract of the medicinal plant Stellaria yunnanensis Franch. Comprehensive spectral analysis was performed utilizing high-resolution mass spectrometry, one- and two-dimensional nuclear magnetic resonance spectroscopy, and experimental and calculated circular dichroism spectroscopy to elucidate the structure of the cyclic nonapeptide (1), which was identified as cyclo-(Tyr-Ala-Thr-Leu-Thr-Ala-Phe-Ala-Thr). Anti-renal fibrosis…

  5. 6.

    Mohammed Y, Moghimi H, Yousef S, Chandrasekaran N, Bibi C, Sukumar S, Grice J, Sakran W, Roberts M. · 2017

Curated sources on file

3
  1. 1.
  2. 2.
  3. 3.
    Note: Primary literature for this commercial cosmetic peptide is limited; cited reviews summarize available preclinical and clinical evidence.

Continue reading